Share Prices & Company Research

Stockbroking

MaxCyte Inc

Current Price 121.50p Bid 120.00p Ask 124.00p Change 0.00%
Last Updated: 21/09/2019 14:32. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

MaxCyte, Inc is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering technology to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery technology, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This enabling technology allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering technology is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also an early-stage drug development company developing CAR therapies via its proprietary platform in immuno-oncology, which allows for development of novel virus-free CAR therapies targeting a broad range of cancers with controlled persistence.

Financial Highlights Year Ended 31/12/2018

Turnover
£16.67m
Operating Profit
£-8.43m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-7.18

Key Personnel

Douglas Arthur Doerfler
Chief Executive Officer
Ronald Evan Holtz
Chief Financial Officer
Dr J Stark Thompson
Non-Executive Chairman
William Wade Brooke
Non-Executive Director
Stanley Charles Erck
Non-Executive Director
John Joseph Johnston
Non-Executive Director
Arthur Michael Mandell
Non-Executive Director

Stock Details

EPIC
MXCT
ISIN
US57777K1060
Shares in Issue
51,357,764
Market cap
£62.66m
Sector

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
122.00p
Bid Price
120.00p
Ask Price
124.00p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
122.00p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
242.00p
52 Week Low
115.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

MaxCyte Inc Intra-day Chart

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
1.8
0.9
Intangible Assets & Goodwill
0.0
0.0
Investments & Other Non-Current Assets
0.0
0.0
Total Non-Current Assets
1.8
0.9
Inventory
2.2
1.4
Trade & Receivables
4.9
3.2
Cash & Receivables
11.3
25.3
Other Current Assets & Assets Held for Resale
4.1
0.7
Total Assets
24.3
31.4

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
6.6
7.2
Long Term Liabilities
5.4
4.6
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
12.0
11.8

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
12.3
19.6

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
0.5
0.5
Minority Interests
0.0
0.0
Retained Earnings
-70.5
-61.6
Share Premium Account
0.0
0.0
Other Equity
82.3
80.7
Total Equity
12.3
19.6

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
-10.5
-9.7
Cashflow Before Financing
-14.3
-10.3
Increase / Decrease in Cash
-14.1
13.6

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
16.7
14.0
Cost of Sales
1.8
1.5
Gross Profit
14.8
12.5
Operating Profit
-8.4
-9.3
Pre-Tax Profit
-8.9
-9.9
Profit / Loss for the Year
-8.9
-9.9
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.